Ornithine carbamoyl transferase deficiency (OCTD), the commonest of the inherited disorders of the urea cycle, is an X linked disorder. Most boys have no detectable enzyme activity and develop severe hyperammonaemia in the neonatal period. Despite intensive treatment most die during the first year of life. In contrast, the clinical manifestation in heterozygous females is very varied, the variation arising because of the random inactivation of X chromosomes during fetal life. Thus, a small proportion of females become hyperammonaemic in early childhood and require careful management to control the biochemical abnormalities. Other heterozygotes have few or no symptoms so that loading tests are needed to identify them as carriers. The most sensitive method is the measurement of orotic acid in the urine after protein or alanine loading.' While this will detect the majority of carriers, occasionally no biochemical abnormality can be detected in an obligate heterozygote2 so a negative result does not exclude heterozygosity. The difficulty for families has been compounded by the fact that until recently no simple method of prenatal diagnosis was available that could be offered to relatives who had only a low probability of The results of DNA analysis (figure) on cultured amniocytes were available four weeks after amniocentesis, the day before the scheduled liver biopsy.
The father (I.1) had the 6-5 kb band, the mother (I.2) had both a 6-5 and 5-8 kb band, and the This couple first presented to us five years ago after their son (11.1) died from hyperammonaemia aged 10 days. There was no detectable OTC activity in his liver. The mother (1.2) has moderate protein intolerance, naturally adopting an average daily pro-tein intake of only 30 g (normal > 60 g). Increased urinary excretion of orotic acid after a protein load confirmed that she was heterozygous for OCTD.
As indicated in the figure, there then followed a further five unsuccessful pregnancies: a spontaneous abortion in the first trimester of a female fetus, the abortion of two male fetuses at 19 to 20 weeks' gestation after prenatal diagnosis of OTC deficiency by liver biopsy, an abortion of a trisomy 13 fetus diagnosed after first trimester chorionic villus sample karyotyping to determine sex, and then a missed abortion detected at seven weeks.
This unfortunate woman presented again six weeks into her seventh pregnancy seeking prenatal diagnosis on any male fetus. Blood for DNA analysis was obtained from her and her husband (I.1), and, fortunately, freshly frozen postmortem liver tissue from which DNA could be obtained was available from the two previously affected male fetuses.
The results of DNA analysis (figure) showed that 1.2 was heterozygous for MspI RFLP, and so chorionic villus sampling was performed at nine weeks' gestation with the object of analysing the fetal karyotype (maternal age 40 years) and for prenatal diagnosis of OTC deficiency by gene tracking with the OTC gene probe. The chorionic villus sample karyotype and results of DNA analysis were available 10 days later. The fetus had a normal female chromosome complement, 46,XX, and had inherited the same X chromosome from her mother as the two previously affected males; she was therefore carrying the OTC deficiency mutation. The father (1.1) had the 6 5 kb allele, 1.2 had both the 6-5 and 5-8 kb alleles, and a previously affected male (11.4) and the fetus (11.7) had just the 6-5 kb band.
While delighted to be carrying a girl, the mother appreciated that there was a small chance that the baby could have significant protein intolerance, but the couple decided that since this risk was small they would continue the pregnancy. However, it was also important to avoid biochemical abnormalities caused by the mother's carrier status. Plasma ammonia and amino acids were monitored throughout her pregnancy. The plasma ammonia remained normal (less than 40 ,umol/l) throughout. However, her plasma arginine concentration was low (15 [imol/l at 15 weeks' gestation). At 20 weeks she was started on a small supplement of arginine (2 g daily) and her plasma arginine concentrations rose to the lower end of the normal range (25 to 30 [tmoll1). This dose continued throughout the pregnancy and the puerperium when the mother wanted to establish breast feeding. The baby is currently well.
Discussion
The way in which the options available to family M changed in the four years after the birth of their first affected boy illustrates the remarkable progress that has been made in genetic prediction for OCTD. When first seen in the genetic clinic, all that could be offered to the couple was fetal sexing after amniocentesis and termination of all males at 18 to 20 weeks' gestation. The introduction of fetal liver biopsy for prenatal diagnosis in males3 offered them the chance to try for a healthy son and limit abortion to only those males who were affected, although this was still relatively late in pregnancy. Chorionic villus sampling permitted fetal sexing in the first trimester and exploitation of the OTC gene specific probe for genetic prediction, once a common RFLP was discovered. The term 'gene tracking' has been applied to the use of RFLP linkage for genetic prediction in these two pregnancies, because the actual mutation itself is not detected. Rozen et In parents with urea cycle disorders because of the metabolic block, arginine becomes an essential or semi-essential amino acid: supplements are needed to prevent hyperammonaemia and to maintain normal growth. On the low protein diet the plasma arginine concentrations of the mother in family M were low and were therefore supplemented to prevent deficiency. We recommend that during pregnancy the diet should be assessed and plasma amino acids and ammonia monitored. 
